Intratumor HER2 heterogeneity has also been associated with reduced pCR [26], which may partly explain our modest pathological response, while immune biomarkers such as tumor-infiltrating lymphocytes correlate with better outcomes [27]. This evidence concerns the gene ERBB2 and neoplasm.